<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: pharmaceutical", fill: "#95b"},
{source: "3: pharmaceutical", target: "3: biotechnology", fill: "#95b"},
{source: "3: biotechnology", target: "3: incorporated into", fill: "#95b"},
{source: "3: incorporated into", target: "3: customers drug manufacturing processes", fill: "#95b"},
{source: "3: pharmaceutical", target: "17: permanent cessation", fill: "#273be2"},
{source: "17: permanent cessation", target: "17: would otherwise", fill: "#273be2"},
{source: "17: would otherwise", target: "17: significant volume", fill: "#273be2"},
{source: "17: significant volume", target: "17: consumables will reduce", fill: "#273be2"},
{source: "17: consumables will reduce", target: "17: negatively impact", fill: "#273be2"},
{source: "17: permanent cessation", target: "23: adequate quality standards", fill: "#fc3"},
{source: "23: adequate quality standards", target: "23: adversely affected", fill: "#fc3"},
{source: "23: adversely affected", target: "23: reputation harmed", fill: "#fc3"},
{source: "23: adequate quality standards", target: "26: customers production line could", fill: "#00ffef"},
{source: "26: customers production line could", target: "26: economic losses", fill: "#00ffef"},
{source: "26: customers production line could", target: "29: continued focus on quality throughout", fill: "#f94d00"},
{source: "29: continued focus on quality throughout", target: "29: company adequately addresses", fill: "#f94d00"},
{source: "29: company adequately addresses", target: "29: occasional", fill: "#f94d00"},
{source: "29: occasional", target: "29: Contents ", fill: "#f94d00"},
{source: "29: Contents ", target: "29: manufacturing", fill: "#f94d00"},
{source: "29: manufacturing", target: "29: operations", fill: "#f94d00"},
{source: "29: continued focus on quality throughout", target: "30: significant", fill: "#6a5acd"},
{source: "30: significant", target: "30: prolonged quality problems", fill: "#6a5acd"},
{source: "30: prolonged quality problems", target: "30: reputation may", fill: "#6a5acd"},
{source: "30: reputation may", target: "30: harmed which may", fill: "#6a5acd"},
{source: "30: harmed which may", target: "30: inability", fill: "#6a5acd"},
{source: "30: inability", target: "30: participate", fill: "#6a5acd"},
{source: "30: participate", target: "30: future customer product opportunities", fill: "#6a5acd"},
{source: "30: future customer product opportunities", target: "30: reduced revenues", fill: "#6a5acd"},
{source: "30: significant", target: "46: Technology ", fill: "#d2b48c"},
{source: "46: Technology ", target: "46: alternatives", fill: "#d2b48c"},
{source: "46: alternatives", target: "46: reduced sales", fill: "#d2b48c"},
{source: "46: Technology ", target: "51: timely basis", fill: "#fc0fc0"},
{source: "51: timely basis", target: "51: customer base", fill: "#fc0fc0"},
{source: "51: customer base", target: "51: new technologies", fill: "#fc0fc0"},
{source: "51: new technologies", target: "51: ineffective", fill: "#fc0fc0"},
{source: "51: timely basis", target: "52: enhance products able", fill: "#ffddf4"},
{source: "52: enhance products able", target: "52: compete with such new technologies", fill: "#ffddf4"},
{source: "52: compete with such new technologies", target: "52: timely manner could", fill: "#ffddf4"},
{source: "52: timely manner could", target: "52: operations", fill: "#ffddf4"},
{source: "52: operations", target: "52: financial condition", fill: "#ffddf4"},
{source: "52: enhance products able", target: "53: timely basis", fill: "#4b5320"},
{source: "53: timely basis", target: "53: customer base", fill: "#4b5320"},
{source: "53: customer base", target: "53: technologies", fill: "#4b5320"},
{source: "53: technologies", target: "53: customers may prove", fill: "#4b5320"},
{source: "53: customers may prove", target: "53: ineffective", fill: "#4b5320"},
{source: "53: timely basis", target: "73: supply chain initiative", fill: "#722f37"},
{source: "73: supply chain initiative", target: "73: improve customer service", fill: "#722f37"},
{source: "73: improve customer service", target: "73: product expertise", fill: "#722f37"},
{source: "73: product expertise", target: "73: concentrate", fill: "#722f37"},
{source: "73: concentrate", target: "73: facilities", fill: "#722f37"},
{source: "73: facilities", target: "73: geographical areas", fill: "#722f37"},
{source: "73: geographical areas", target: "73: which there", fill: "#722f37"},
{source: "73: which there", target: "73: qualified staff", fill: "#722f37"},
{source: "73: supply chain initiative", target: "START_HERE", fill: "#722f37"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Diversified Commercial Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Protest demonstrations</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Collaborate</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Life_Insurance_Corporation">Life Insurance Corporation</a></td>
      <td>Life Insurance Corporation of India (LIC) is an Indian statutory insurance and investment corporation headquartered in the city of Mumbai, India. It is under the ownership of Government of India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ivor_Montagu">Ivor Montagu</a></td>
      <td>Ivor Goldsmid Samuel Montagu (23 April 1904, in Kensington, London – 5 November 1984, in Watford) was an English filmmaker, screenwriter, producer, film critic, writer, table tennis player, and Communist activist in the 1930s. He helped to develop a lively intellectual film culture in Britain during the interwar years, and was also the founder of the International Table Tennis Federation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Day_the_Music_Died">The Day the Music Died</a></td>
      <td>On February 3, 1959, American rock and roll musicians Buddy Holly, Ritchie Valens, and "The Big Bopper" J. P. Richardson were killed in a plane crash near Clear Lake, Iowa, together with pilot Roger Peterson. The event later became known as "The Day the Music Died" after singer-songwriter Don McLean referred to it as such in his 1971 song "American Pie".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_American_Free_Trade_Agreement">North American Free Trade Agreement</a></td>
      <td>The North American Free Trade Agreement (NAFTA ; Spanish: Tratado de Libre Comercio de América del Norte, TLCAN; French: Accord de libre-échange nord-américain, ALÉNA) was an agreement signed by Canada, Mexico, and the United States that created a trilateral trade bloc in North America. The agreement came into force on January 1, 1994, and superseded the 1988 Canada–United States Free Trade Agreement between the United States and Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Flight_Facilities">Flight Facilities</a></td>
      <td>Flight Facilities is an Australian electronic producer duo that also performs as Hugo &amp; Jimmy. In 2009, they began mixing songs by other artists before crafting their own original material.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/NASA_facilities">NASA facilities</a></td>
      <td>There are NASA facilities across the United States and around the world. NASA Headquarters in Washington, DC provides overall guidance and political leadership to the agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pedestrian_facilities">Pedestrian facilities</a></td>
      <td>Pedestrian facilities include retail shops, museums, mass events (such as festivals or concert halls), hospitals, transport hubs (such as train stations or airports), sports infrastructure (such as stadiums) and religious infrastructures. The transport mode in such infrastructures is mostly walking, with rare exceptions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Facilities_Society">The Facilities Society</a></td>
      <td>The Facilities Society was founded in the UK on 9 December 2008 as a not-for-profit company limited by guarantee (registered in England nr. 6769050).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facilities_engineering">Facilities engineering</a></td>
      <td>Facilities engineering evolved from "plant engineering" in the early 1990s as U.S. workplaces became more specialized. Practitioners preferred this term because it more accurately reflected the multidisciplinary demands for specialized conditions in a wider variety of indoor environments, not merely manufacturing plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Attacks_on_U.S._diplomatic_facilities">Attacks on U.S. diplomatic facilities</a></td>
      <td>The United States maintains numerous embassies and consulates around the world, many of which are in war-torn countries or other dangerous areas.\n\n\n== Diplomatic Security ==\nThe Regional Security Office is staffed by Special Agents of the Diplomatic Security Service (DSS), and is responsible for all security, protection, and law enforcement operations in the embassy or consulate.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MILLIPORE CORP /MA      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>Lack of early success with our <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> customers     can shut us out of future business with those customers</td>
    </tr>
    <tr>
      <td>Many  of  the products we sell to the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     customers are <font color="blue">incorporated into</font> the customers’ <font color="blue">drug <font color="blue">manufacturing</font> process</font>es</td>
    </tr>
    <tr>
      <td>In some cases, once a <font color="blue">customer chooses</font> a <font color="blue">particular product</font> for use in a     <font color="blue">drug <font color="blue">manufacturing</font> process</font>, it is unlikely that the <font color="blue">customer will later</font>     switch to a <font color="blue">competing alternative</font></td>
    </tr>
    <tr>
      <td>In many cases the <font color="blue"><font color="blue">regulatory</font> license</font> for     the <font color="blue">product will specify</font> the <font color="blue">separation products qualified</font> for use in the     process</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font>the <font color="blue">regulatory</font> approvals needed for a change in the     <font color="blue">manufacturing</font>  process  is  time  consuming,  expensive and uncertain</td>
    </tr>
    <tr>
      <td>Accordingly,  if we fail to convince a <font color="blue">pharmaceutical</font> or <font color="blue">bio<font color="blue">technology</font></font>     customer to choose our <font color="blue">products early</font> in its <font color="blue">manufacturing</font> design phase, we     may  <font color="blue">lose <font color="blue">permanently</font></font> the <font color="blue">opportunity</font> to <font color="blue">participate</font> in the customer’s     production of <font color="blue">such product</font></td>
    </tr>
    <tr>
      <td>Because we <font color="blue">face vigorous competition</font> in this     <font color="blue">market from companies with</font> substantial financial and <font color="blue">technical resources</font>, we     run the risk that our <font color="blue"><font color="blue">competitors</font> will win <font color="blue">significant</font> early</font> business with a     customer making it <font color="blue">difficult</font> for us to recover that <font color="blue">opportunity</font></td>
    </tr>
    <tr>
      <td>The suspension or <font color="blue">termination</font> of production of a customer’s therapeutic     product  may  result  in the <font color="blue">abrupt suspension</font> or <font color="blue">termination</font> of their     purchases of our products, resulting in an <font color="blue">unexpected reduction</font> in our     revenue</td>
    </tr>
    <tr>
      <td><font color="blue">Success  </font>in  our  <font color="blue">Bioprocess  </font>business  <font color="blue">substantially</font>  depends  on the     <font color="blue">incorporation</font> of our <font color="blue">products into</font> a customer’s <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td>If     this “design in” is achieved, we <font color="blue">will likely</font> have the <font color="blue">opportunity</font> to sell     <font color="blue">consumable products</font> to the <font color="blue">customer during</font> the life cycle of the customer’s     product,  <font color="blue">which could continue</font> for many years</td>
    </tr>
    <tr>
      <td>Our planning and growth     <font color="blue">projections</font> are built in part on the <font color="blue">volume <font color="blue">assumption</font>s deriving from</font> these     <font color="blue">customer successes</font></td>
    </tr>
    <tr>
      <td>If a customer stops production of its product, either     <font color="blue">temporarily</font> or <font color="blue">permanently</font>, our sales to the customer for the applicable     <font color="blue">product will drop</font> or stop</td>
    </tr>
    <tr>
      <td>A <font color="blue">customer may suspend</font> or <font color="blue">terminate production</font> of     a  product, either voluntarily or <font color="blue">involuntarily</font>, and related sales and     <font color="blue">distribution</font>  for  many reasons</td>
    </tr>
    <tr>
      <td>These may include adverse <font color="blue">regulatory</font>,     <font color="blue">competitive</font>, legal or <font color="blue">economic circumstances</font></td>
    </tr>
    <tr>
      <td>We have had in the past, and     expect to have in the future, situations in which a <font color="blue">customer suspends</font> its     purchases of our products</td>
    </tr>
    <tr>
      <td>A suspension or <font color="blue">permanent cessation</font> of a process     in which we <font color="blue">would otherwise</font> anticipate selling a <font color="blue"><font color="blue">significant</font> volume</font> of     <font color="blue">consumables will reduce</font> our revenues and <font color="blue">negatively impact</font> our earnings</td>
    </tr>
    <tr>
      <td><font color="blue">Disruptions </font>in the supply of <font color="blue"><font color="blue">raw materials</font> from</font> our <font color="blue"><font color="blue">single source supplier</font>s</font>     could result in a <font color="blue"><font color="blue">significant</font> <font color="blue">disruption</font></font> in sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our  products  are  made from a wide variety of <font color="blue">raw materials</font> that are     <font color="blue">generally available from alternate sources</font> of supply</td>
    </tr>
    <tr>
      <td>However, certain     critical <font color="blue">raw materials</font> and supplies required for the production of some of     our <font color="blue">principal products</font> are <font color="blue">available only from</font> a <font color="blue">single supplier</font></td>
    </tr>
    <tr>
      <td>Such raw     <font color="blue">materials cannot</font> be obtained from other <font color="blue">sources without <font color="blue">significant</font> delay</font> or     at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">such suppliers</font> were to limit or <font color="blue">terminate production</font> or otherwise     fail to supply these materials for any reason, such failures could have a     material <font color="blue">adverse impact on</font> our <font color="blue">product sales</font> and our business</td>
    </tr>
    <tr>
      <td>If we fail to maintain <font color="blue">adequate <font color="blue">quality standards</font></font> for our products and     services, our business may be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> and our <font color="blue">reputation harmed</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> customers are subject to rigorous     <font color="blue">quality standards</font> in order to obtain and to maintain <font color="blue">regulatory</font> approval of     their products and the <font color="blue">manufacturing</font> processes that <font color="blue">generate them</font></td>
    </tr>
    <tr>
      <td>A failure     to sustain the <font color="blue">specified quality <font color="blue">requirements</font></font>, including the integrity of     the <font color="blue">separations function</font> performed by our products, could result in the loss     of the applicable <font color="blue"><font color="blue">regulatory</font> license</font></td>
    </tr>
    <tr>
      <td>In addition, any delays or quality     lapses  in  our customer’s production line could result in substantial     <font color="blue">economic losses</font> to us</td>
    </tr>
    <tr>
      <td>For example, large <font color="blue">production lots</font> of <font color="blue">biotherapeutics</font>     are very delicate and expensive and a failure of a <font color="blue">separation membrane could</font>     result in the <font color="blue">contamination</font> of the entire lot, requiring its <font color="blue">destruction</font></td>
    </tr>
    <tr>
      <td>We     also  perform  services  that  may  be  considered an extension of our     customers’ <font color="blue">manufacturing</font> and quality assurance processes, which also require     the maintenance of <font color="blue">prescribed levels</font> of quality</td>
    </tr>
    <tr>
      <td>Although we believe that     our <font color="blue">continued focus on quality <font color="blue">throughout</font></font> the <font color="blue">company adequately addresses</font>     these  risks,  there  can  be no assurance that we will not experience     <font color="blue">occasional</font>                                           14     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font>or systemic quality lapses in our <font color="blue">manufacturing</font> and service <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If     we experience <font color="blue">significant</font> or <font color="blue">prolonged quality problems</font>, our business and     <font color="blue">reputation may</font> be harmed, which may result in the loss of customers, our     <font color="blue">inability</font> to <font color="blue">participate</font> in <font color="blue">future customer product <font color="blue">opportunities</font></font>, and     <font color="blue"><font color="blue">reduced revenue</font>s</font> and earnings</td>
    </tr>
    <tr>
      <td>We may be unable to establish and to maintain <font color="blue"><font color="blue">collaborative</font> <font color="blue">development</font></font> and     <font color="blue">marketing <font color="blue"><font color="blue">relationship</font>s</font> with</font> business partners, which could result in a     decline in revenues or <font color="blue">slower than</font> anticipated <font color="blue"><font color="blue">growth rate</font>s</font></td>
    </tr>
    <tr>
      <td>As a part of our business strategy, we have formed, and intend to continue     to form, strategic alliances and marketing and <font color="blue">distribution</font> <font color="blue">arrangements</font>     with corporate partners relating to the <font color="blue">development</font>, <font color="blue">commercialization</font>,     marketing and <font color="blue">distribution</font> of certain of our existing and <font color="blue">potential products</font>     to increase our revenues and to leverage our product and <font color="blue">service offerings</font></td>
    </tr>
    <tr>
      <td>Our  success  will  depend,  in part, on our ability to maintain these     <font color="blue"><font color="blue">relationship</font>s</font> and to cultivate <font color="blue">additional</font> corporate alliances with such     companies</td>
    </tr>
    <tr>
      <td>In 2005, we <font color="blue">entered into</font> a <font color="blue">joint <font color="blue">development</font> <font color="blue">agreement</font> with</font>     Gen-Probe Incorporated</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that our historical <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font> will be     <font color="blue">commercially</font>  successful, that we will be able to <font color="blue">negotiate <font color="blue">additional</font></font>     <font color="blue">collaborative</font>   <font color="blue"><font color="blue">relationship</font>s</font>,   that  such  <font color="blue">additional</font>  <font color="blue">collaborative</font>     <font color="blue"><font color="blue">relationship</font>s</font> will be available to us on acceptable terms, or that any such     <font color="blue"><font color="blue">relationship</font>s</font>, if established, will be <font color="blue">commercially</font> successful</td>
    </tr>
    <tr>
      <td>In addition,     we  <font color="blue">cannot ensure</font> that <font color="blue">parties with which</font> we have established, or will     establish, <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font> will not, <font color="blue">either directly</font> or in     <font color="blue">collaboration</font>  with others, pursue alternative <font color="blue">technologies</font> or develop     <font color="blue">alternative products</font> in addition to, or instead of, our products</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>parties  may  also  be  acquired  by  our <font color="blue">competitors</font> to terminate our     <font color="blue">relationship</font></td>
    </tr>
    <tr>
      <td>They may also experience financial or other <font color="blue">difficult</font>ies that     lessen their value to us and to our customers</td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> and     <font color="blue">opportunities</font>  for  <font color="blue">growth may</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by our failure to     establish and maintain successful <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font></td>
    </tr>
    <tr>
      <td>Demand  for  our  <font color="blue">bioprocess</font>  products and services are subject to the     <font color="blue">commercial success</font> of our customers’ products which may vary for reasons     outside our control</td>
    </tr>
    <tr>
      <td>Even if we are successful in <font color="blue">securing participation</font> for our products in a     customer’s <font color="blue">manufacturing</font> process, sales of many of our <font color="blue">bioprocess</font> products     and <font color="blue">services remain <font color="blue"><font color="blue">dependent</font> on</font></font> the timing and volume of the customer’s     production, over which we have no control</td>
    </tr>
    <tr>
      <td>The customer’s demand for our     <font color="blue">products will depend on</font> the <font color="blue">regulatory</font> approval and <font color="blue">commercial success</font> of     the  <font color="blue">supported product</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> process is complex, lengthy and     expensive  and can often take years to complete, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Commercial     </font>success of a customer’s product, which would drive demand in production and     <font color="blue">commensurate demand</font> for our products and services, is <font color="blue"><font color="blue">dependent</font> on</font> many     factors,  some  of  which  can  change rapidly, despite early positive     <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">cancellation by</font> a customer of volume <font color="blue">manufacturing</font>     may harm our revenues and earnings</td>
    </tr>
    <tr>
      <td><font color="blue">Technology </font><font color="blue">innovations</font> in the markets that we serve may create <font color="blue">alternatives</font>     to our products and result in <font color="blue">reduced sales</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">customers constantly attempt</font> to reduce their <font color="blue">manufacturing</font> costs and to     <font color="blue">improve product quality</font></td>
    </tr>
    <tr>
      <td><font color="blue">Technology </font><font color="blue">innovations</font> to which our current and     <font color="blue">potential customers would</font> have <font color="blue">access <font color="blue">could reduce</font></font> or eliminate their need     for our membrane or <font color="blue"><font color="blue">chromatography</font> products</font></td>
    </tr>
    <tr>
      <td>For example, if a new membrane     or <font color="blue"><font color="blue">chromatography</font> <font color="blue">technology</font></font> of one of our <font color="blue">competitors</font> is <font color="blue">accepted by</font> the     <font color="blue">pharmaceutical</font> or <font color="blue">bio<font color="blue">technology</font></font> industry as a market standard, sales of our     membrane  or  <font color="blue"><font color="blue">chromatography</font> products</font> would be <font color="blue">negatively impact</font>ed</td>
    </tr>
    <tr>
      <td>In     addition, a <font color="blue">disruptive <font color="blue">technology</font></font> that reduces or <font color="blue">eliminates</font> the use of     membranes  or  <font color="blue">chromatography</font>  would <font color="blue">negatively impact</font> the sale of our     products</td>
    </tr>
    <tr>
      <td>We may be unable to respond on a <font color="blue">timely basis</font> to the changing     needs  of our <font color="blue">customer base</font> and the <font color="blue">new <font color="blue">technologies</font></font> we design for our     customers  may  prove to be <font color="blue">ineffective</font></td>
    </tr>
    <tr>
      <td>Our failure to develop and to     introduce or to <font color="blue">enhance products able</font> to <font color="blue">compete with</font> such <font color="blue">new <font color="blue">technologies</font></font>     in a <font color="blue"><font color="blue">timely manner</font> could</font> have a material adverse effect on our business,     results of <font color="blue">operations</font>, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We may be unable to respond     on a <font color="blue">timely basis</font> to the changing needs of our <font color="blue">customer base</font> and the new     <font color="blue">technologies</font> we design for our <font color="blue"><font color="blue">customers may</font> prove</font> to be <font color="blue">ineffective</font></td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>We  may be unable to realize our <font color="blue">growth strategy</font> if we cannot identify     suitable <font color="blue">acquisition</font> <font color="blue">opportunities</font> in the future</td>
    </tr>
    <tr>
      <td>As part of our business strategy, we expect to continue to grow our business     <font color="blue">through <font color="blue">acquisition</font>s</font> of <font color="blue">technologies</font> or companies</td>
    </tr>
    <tr>
      <td>We may not identify or     complete <font color="blue">complementary <font color="blue">acquisition</font>s</font> in a <font color="blue">timely manner</font>, on a cost-effective     basis, or at all</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">compete with</font> other companies, including     large, well funded <font color="blue">competitors</font>, to acquire <font color="blue">suitable targets</font>, and may not be     able to acquire <font color="blue">certain targets</font> that we seek</td>
    </tr>
    <tr>
      <td>There can be no assurance that     we will be able to execute this component of our <font color="blue">growth strategy</font> which may     harm our business and hinder our <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>To achieve desired <font color="blue"><font color="blue">growth rate</font>s</font> as we <font color="blue">become larger</font>, we <font color="blue">may seek larger</font> or     <font color="blue">public companies as potential <font color="blue">acquisition</font> candidates</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">acquisition</font> of a     public company may involve <font color="blue">additional</font> risks, including the potential for     lack  of <font color="blue">recourse against public <font color="blue">shareholders</font></font> for undisclosed material     <font color="blue">liabilities</font> of the acquired business</td>
    </tr>
    <tr>
      <td>In addition, if we were to proceed     with one or more <font color="blue">significant</font> future <font color="blue">acquisition</font>s in which the <font color="blue">consideration</font>     consisted of cash, a substantial portion of our <font color="blue">available cash resources</font>     could be used</td>
    </tr>
    <tr>
      <td>Our  continued  growth  is <font color="blue"><font color="blue">dependent</font> on</font> our <font color="blue">development</font> and successful     <font color="blue">commercialization</font> of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Our  future  success  will  depend  in  part on timely <font color="blue">development</font> and     <font color="blue">introduction</font> of <font color="blue">new products</font> that address changing <font color="blue">market <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>We     believe that successful new product <font color="blue">introduction</font>s provide a <font color="blue">significant</font>     <font color="blue">competitive</font>  advantage because customers make an <font color="blue">investment</font> of time in     selecting and learning to use a new product</td>
    </tr>
    <tr>
      <td><font color="blue">Customers </font>are reluctant to     switch to a <font color="blue">competing product</font> after making their <font color="blue">initial selection</font></td>
    </tr>
    <tr>
      <td>To the     extent that we fail to introduce new and innovative products, we may lose     market share to our <font color="blue">competitors</font>, which will be <font color="blue">difficult</font> or impossible to     regain</td>
    </tr>
    <tr>
      <td>An <font color="blue">inability</font>, for <font color="blue">technological</font> or other reasons, to <font color="blue">successfully</font>     develop and introduce new <font color="blue">products could</font> reduce our <font color="blue">growth rate</font> or otherwise     damage our business</td>
    </tr>
    <tr>
      <td>In the past, we have experienced, and are likely to     experience in the future, delays in the <font color="blue">development</font> and <font color="blue">introduction</font> of     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we will keep pace with the rapid rate of     change in <font color="blue">life sciences research</font>, or that our <font color="blue">new products</font> will adequately     meet the <font color="blue">requirements</font> of the marketplace or achieve <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>If we fail to attract, hire, develop and retain <font color="blue">qualified personnel</font>, we may     not  be  able  to  design, <font color="blue">manufacture</font>, market or sell our products or     <font color="blue">successfully</font> grow our business</td>
    </tr>
    <tr>
      <td><font color="blue">Competition  </font>for  <font color="blue">individuals</font>  with skills including sales, marketing,     research, product <font color="blue">development</font>, <font color="blue">engineering</font> and others is strong and we may     not be able to secure the personnel we need</td>
    </tr>
    <tr>
      <td>The loss of the services of any     <font color="blue">key personnel</font>, or our <font color="blue">inability</font> to <font color="blue">hire new personnel with</font> the requisite     skills, <font color="blue">could restrict</font> our ability to develop <font color="blue">new products</font> and services or     <font color="blue">enhance existing products</font> and services in a <font color="blue">timely manner</font>, sell products to     our customers or manage our business <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td>As part of our global     <font color="blue">supply <font color="blue">chain initiative</font></font> to <font color="blue">improve customer service</font> and to amplify our     <font color="blue">product expertise</font>, we have begun to <font color="blue">concentrate</font> our <font color="blue">facilities</font> in fewer     <font color="blue">geographical areas</font> in <font color="blue">which there</font> is high demand for <font color="blue">qualified staff</font></td>
    </tr>
    <tr>
      <td>If we do not achieve the anticipated <font color="blue">cost benefits</font> of our <font color="blue">global supply</font>     <font color="blue">chain initiative</font>, our future <font color="blue">profitability</font> may be <font color="blue"><font color="blue">adversely</font> impacted</font></td>
    </tr>
    <tr>
      <td>In 2004, we began a <font color="blue">coordinated program</font> to reorganize and to <font color="blue">consolidate</font> our     <font color="blue">worldwide supply chain function</font>, including our <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>One     of the purposes of this initiative was to reduce our overall <font color="blue">manufacturing</font>     costs and improve our gross <font color="blue">margin performance over</font> time</td>
    </tr>
    <tr>
      <td>A <font color="blue">reorganization</font>     with this level of <font color="blue">complexity</font> and <font color="blue">worldwide scope</font> is subject to various     <font color="blue">execution risks</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">encounter unexpected delays</font> or costs, our gross     <font color="blue">margin may</font> not <font color="blue">improve as</font> we had anticipated</td>
    </tr>
    <tr>
      <td>For example, delays in the     required <font color="blue">preparation</font> and <font color="blue">improvements</font> of one of our primary <font color="blue">facilities</font> may     defer the transfer of <font color="blue">production from</font> our <font color="blue">facilities</font> targeted for closing,     resulting  in  continued  carrying  costs  for  such <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">preparation</font>s are subject to many factors, including the <font color="blue">availability</font> of     <font color="blue"><font color="blue">construction</font> materials</font> and sophisticated production equipment, qualified     <font color="blue"><font color="blue">construction</font> labor</font> and qualified <font color="blue">additional</font> production personnel</td>
    </tr>
    <tr>
      <td>Even after     <font color="blue">completion</font> of the program, we may not be able to obtain and maintain the     anticipated <font color="blue">efficiencies</font> in our <font color="blue">manufacturing</font> and supply chain, which would     limit our ability to improve or maintain our gross margins</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font>If our <font color="blue">consolidate</font>d <font color="blue">manufacturing</font> <font color="blue">operations</font> were disrupted, we may be     unable to <font color="blue">supply products</font> to our customers and achieve expected revenues</td>
    </tr>
    <tr>
      <td>We are in the process of executing a coordinated <font color="blue">reorganization</font> of our     supply chain and <font color="blue">manufacturing</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In an effort to better serve our     customers  and  to  attain <font color="blue">efficiencies</font> of scale and expertise, we are     <font color="blue">consolidating</font> the majority of our production <font color="blue">facilities</font> into three centers     of excellence in Jaffrey, New Hampshire, Molsheim, France and Cork, Ireland</td>
    </tr>
    <tr>
      <td>Each of these <font color="blue">facilities</font> serves as our primary production <font color="blue">facility</font> for     specific product lines</td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of production, however, exposes     us to a <font color="blue">greater risk</font> of <font color="blue">disruption</font> to our ability to <font color="blue">manufacture</font> and supply     our products</td>
    </tr>
    <tr>
      <td>If <font color="blue">operation at</font> any of these <font color="blue">facilities</font> were disrupted, we may     not  be able to deliver products to our customers and achieve expected     revenues or earnings</td>
    </tr>
    <tr>
      <td>If we were unable to <font color="blue">reestablish production</font> in a     <font color="blue">timely manner</font>, we <font color="blue">may lose customers</font> and have <font color="blue">difficult</font>y regaining them</td>
    </tr>
    <tr>
      <td>It     is <font color="blue">uncertain whether</font> the <font color="blue">safety measures</font> and <font color="blue">contingency</font> plans that we have     implemented or may implement will <font color="blue">successfully</font> address the risks that may     arise if production is disrupted</td>
    </tr>
    <tr>
      <td>Also, there can be no assurance that the     insurance that we maintain to <font color="blue">protect against</font> business <font color="blue">interruption loss</font>     will be adequate or that <font color="blue">such insurance <font color="blue">will continue</font></font> to <font color="blue">remain available on</font>     acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>The extent of the coverage of our insurance     could limit our ability to mitigate for lost sales and could result in such     <font color="blue">losses <font color="blue">materially</font></font> and <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ing</font> our operating results</td>
    </tr>
    <tr>
      <td>Sales  of  several  of our products are <font color="blue"><font color="blue">dependent</font> on</font> a small number of     customers, the loss of which may harm our business and result in a reduction     in revenues and earnings</td>
    </tr>
    <tr>
      <td>No <font color="blue">single customer represents</font> more than 10prca of our <font color="blue">annual sales</font></td>
    </tr>
    <tr>
      <td>However,     sales  of  some  of  our products are <font color="blue"><font color="blue">dependent</font> on</font> a limited number of     customers, who account for a <font color="blue">significant</font> portion of such sales</td>
    </tr>
    <tr>
      <td>Some of     these products are in areas in which we plan to grow <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>The loss     of <font color="blue">such key customers</font> for <font color="blue">such product</font>s, or a <font color="blue">significant</font> reduction in sales     to  those  customers, could <font color="blue">significant</font>ly reduce our revenues in these     products and <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">future growth</font> in <font color="blue">such markets</font></td>
    </tr>
    <tr>
      <td>We  may  become  involved  in disputes regarding our patents and other     <font color="blue">intellectual property</font> rights, which could result in <font color="blue">prohibition on</font> the use     of  <font color="blue">certain <font color="blue">technology</font></font> in current or planned products, exposure of the     business to <font color="blue">significant</font> <font color="blue">liability</font> and diversion of management’s focus</td>
    </tr>
    <tr>
      <td>We and our major <font color="blue">competitors</font> spend substantial time and resources developing     and  patenting new and improved products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Many of our     products are based on complex, rapidly developing <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Although we     try to identify all <font color="blue">relevant <font color="blue">third party</font> patents</font> and <font color="blue">intellectual property</font>     rights, these <font color="blue">products could</font> be developed by the business <font color="blue">without knowledge</font>     of published or <font color="blue">unpublished patent applications</font> that cover or use some     aspect of these <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We have been and may in the future be sued by     <font color="blue">third parties</font> alleging that we are infringing their <font color="blue">intellectual property</font>     rights</td>
    </tr>
    <tr>
      <td>These lawsuits are expensive, take <font color="blue">significant</font> time and divert     management’s focus from other business concerns</td>
    </tr>
    <tr>
      <td>If we are found to be     infringing the <font color="blue">intellectual property</font> of others, we could be required to stop     the <font color="blue">infringing activity</font>, or we may be required to <font color="blue">design around</font> or license     the <font color="blue">intellectual property</font> in question</td>
    </tr>
    <tr>
      <td>If we are unable to obtain a required     <font color="blue">license on</font> acceptable terms, or are unable to <font color="blue">design around</font> any <font color="blue">third party</font>     patent, we may be unable to sell some of our products and services, which     could result in <font color="blue">reduced revenue</font></td>
    </tr>
    <tr>
      <td>In addition, if we do not prevail, a court     <font color="blue">may find damages</font> or award other remedies in favor of the <font color="blue">opposing party</font> in     any of these suits, which may <font color="blue"><font color="blue">adversely</font> affect</font> our earnings</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> must comply with environmental statutes and <font color="blue">regulations</font>, and     any failure to <font color="blue">comply could</font> result in extensive <font color="blue">costs which would harm</font> our     business</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of some of our <font color="blue">products involves</font> the use, transportation,     storage and disposal of <font color="blue">hazardous</font> or <font color="blue">toxic materials</font> and is subject to     <font color="blue">various environmental protection</font> and <font color="blue">occupational health</font> and <font color="blue">safety laws</font> and     <font color="blue">regulations</font> in the countries in which we operate</td>
    </tr>
    <tr>
      <td>This has exposed us in the     past,  and  could  expose  us  in  the  future, to risks of <font color="blue">accidental</font>     <font color="blue">contamination</font> and events of non-compliance with <font color="blue">environmental laws</font></td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">occurrences could</font> result in <font color="blue">regulatory</font> enforcement or <font color="blue">personal injury</font> and     property  damage  claims  or  could  lead to a shutdown of some of our     <font color="blue">operations</font>, which could have an adverse effect on our business and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently incur costs</font> to <font color="blue">comply with <font color="blue">environmental laws</font></font>     and <font color="blue">regulations</font> and these <font color="blue">costs may become</font> more <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font>The <font color="blue">environmental laws</font> of many <font color="blue">jurisdictions impose actual</font> and potential     <font color="blue"><font color="blue">obligations</font> on us</font> to <font color="blue">remediate contaminated sites</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">obligations</font> may</font>     relate to sites:           •   that we currently own or operate;           •   that we formerly owned or operated; or           •   where waste from our <font color="blue">operations</font> was disposed</td>
    </tr>
    <tr>
      <td>These <font color="blue">environmental remediation <font color="blue">obligations</font> <font color="blue">could reduce</font></font> our operating     results</td>
    </tr>
    <tr>
      <td>In  particular,  our  accruals  for these <font color="blue"><font color="blue">obligations</font> may</font> be     insufficient if the <font color="blue"><font color="blue">assumption</font>s underlying</font> the <font color="blue">accruals prove</font> incorrect or     if  we  are  held  responsible  for <font color="blue">additional</font>, currently undiscovered     <font color="blue">contamination</font></td>
    </tr>
    <tr>
      <td>A substantial fine or penalty, the payment of <font color="blue">significant</font> environmental     <font color="blue">remediation costs</font> or the loss of a permit or other <font color="blue">authorization</font> to operate     or engage in our <font color="blue">ordinary course</font> of business could result in material,     <font color="blue">unanticipated</font>  expenses and the possible <font color="blue">inability</font> to <font color="blue">satisfy customer</font>     demand</td>
    </tr>
    <tr>
      <td>If our efforts to integrate acquired or <font color="blue">licensed <font color="blue">businesses</font></font> or <font color="blue">technologies</font>     into our business are not successful, our business could be harmed</td>
    </tr>
    <tr>
      <td>As part of our business strategy, we expect to continue to grow our business     <font color="blue">through <font color="blue">acquisition</font>s</font> of <font color="blue">technologies</font> or of companies that <font color="blue">offer products</font>,     services and <font color="blue">technologies</font> that we believe <font color="blue">would complement</font> our <font color="blue">technologies</font>     and services</td>
    </tr>
    <tr>
      <td>In 2005, we acquired NovAseptic AB and MicroSafe BV       Managing these <font color="blue">acquisition</font>s and any future <font color="blue">acquisition</font>s will entail numerous     operational, legal and <font color="blue">financial risks</font>, including:           •   <font color="blue">difficult</font>ies in assimilating <font color="blue">new <font color="blue">technologies</font></font>, <font color="blue">operations</font>, sites and     personnel;           •   diversion of resources and <font color="blue">management attention from</font> our existing     <font color="blue">businesses</font> and <font color="blue">technologies</font>;           •   <font color="blue">inability</font> to maintain uniform <font color="blue">quality standards</font>, controls, and     procedures;           •   <font color="blue">inability</font> to retain <font color="blue">key employees</font> of any acquired <font color="blue">businesses</font> or hire     enough <font color="blue">qualified personnel</font> to staff any new or expanded <font color="blue">operations</font>;           •   <font color="blue">impairment</font> or loss of <font color="blue"><font color="blue">relationship</font>s</font> with key customers of acquired     <font color="blue">businesses</font>;           •   issuance of <font color="blue">dilutive equity securities</font>;           •   incurrence or <font color="blue">assumption</font> of debt;           •   exposure to unknown or <font color="blue">unanticipated</font> <font color="blue">liabilities</font>;           •   <font color="blue">additional</font> expenses associated with future amortization or <font color="blue">impairment</font>     of acquired <font color="blue"><font color="blue">intangible asset</font>s</font> or potential <font color="blue">businesses</font>; and           •   exposure to federal, state, local and foreign tax <font color="blue">liabilities</font> in     <font color="blue">connection with</font> any <font color="blue">acquisition</font> or the <font color="blue">integration</font> of any acquired     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Our failure to address these risks <font color="blue">successfully</font> in the <font color="blue">future could harm</font> our     business and prevent our <font color="blue">achievement</font> of anticipated growth</td>
    </tr>
    <tr>
      <td>Our sales may be <font color="blue">negatively affected by</font> the <font color="blue">implementation</font> of <font color="blue">second source</font>     <font color="blue">programs by</font> our customers</td>
    </tr>
    <tr>
      <td>For  many customers, we are the <font color="blue">single source supplier</font> for one or more     critical  <font color="blue">components</font>  used  in their <font color="blue">production lines</font></td>
    </tr>
    <tr>
      <td>We are aware of     customers that have begun to implement <font color="blue">second sourcing programs</font> to reduce     the  <font color="blue">potential risk</font> of <font color="blue">disruption</font>s to their <font color="blue">production due</font> to a supply     bottleneck</td>
    </tr>
    <tr>
      <td>These can include <font color="blue">diversifying purchases</font> of one component among     vendors  or  spreading the sources of <font color="blue">components</font> of a process, such as     purification, among different suppliers</td>
    </tr>
    <tr>
      <td>If, as a result of these second     sourcing programs, existing customers were to choose another company to     supply <font color="blue">components</font> that we <font color="blue">currently supply</font>, or if we <font color="blue">lose future</font> business     <font color="blue">opportunities</font> for which we <font color="blue">would otherwise</font> be qualified, our <font color="blue">future revenues</font>     may be harmed</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>Our use of <font color="blue">third party</font> <font color="blue">manufacture</font>rs exposes us to <font color="blue">increased risks</font> that may     affect our ability to supply our customers</td>
    </tr>
    <tr>
      <td>As part of our efforts to <font color="blue">consolidate</font> our <font color="blue">manufacturing</font> <font color="blue">operations</font>, we have     increased the outsourcing of certain <font color="blue">manufacturing</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For example,     in  2006, we will be <font color="blue">migrating most</font> of our standard <font color="blue">bioprocess</font> systems     production  to  a  company in India in which we have a minority equity     interest</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">often source products</font> resulting from <font color="blue">collaborative</font>     <font color="blue">development</font> <font color="blue"><font color="blue">relationship</font>s</font> from such <font color="blue">development</font> partners</td>
    </tr>
    <tr>
      <td>If  any  of our <font color="blue">third party</font>     <font color="blue">manufacture</font>rs experiences delays, <font color="blue">disruption</font>s, <font color="blue">capacity</font> <font color="blue">constraints</font> or     quality  control  problems  in its <font color="blue">manufacturing</font> <font color="blue">operations</font> or becomes     insolvent, then product shipments to our customers could be delayed, which     would  decrease  our  revenues  and  harm our <font color="blue">competitive</font> position and     reputation</td>
    </tr>
    <tr>
      <td>Because we <font color="blue">compete directly with one</font> of our <font color="blue">key suppliers</font> and one of our     <font color="blue">significant</font> <font color="blue">distributor</font>s, our results of <font color="blue">operations</font> could be <font color="blue">adversely</font>     affected if either of these <font color="blue">parties <font color="blue">discontinues</font></font> or <font color="blue">materially</font> changes the     terms of the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We source a key raw material from a <font color="blue">significant</font> competitor in the market     into  which we sell the resulting products</td>
    </tr>
    <tr>
      <td>Although we purchase these     materials  under  a  supply  <font color="blue">agreement</font>  <font color="blue">which provides</font> for some supply     <font color="blue">protections</font>, our business could be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if this supplier     <font color="blue">discontinues</font>  selling the <font color="blue">raw materials</font> to us</td>
    </tr>
    <tr>
      <td>In addition, one of our     <font color="blue">competitors</font> also serves as a <font color="blue">significant</font> <font color="blue">distributor</font></td>
    </tr>
    <tr>
      <td>If this <font color="blue">distributor</font>     <font color="blue">discontinued selling</font> our products or <font color="blue">materially</font> changed the terms, our sales     and <font color="blue">earnings could</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> in the short term</td>
    </tr>
    <tr>
      <td>If we experience a <font color="blue"><font color="blue">significant</font> <font color="blue">disruption</font></font> in our information <font color="blue">technology</font>     systems or if we fail to implement <font color="blue">new systems</font> and software <font color="blue">successfully</font>,     our business could be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on one centralized</font> information <font color="blue">system <font color="blue">throughout</font></font> our company to     process orders, manage inventory and <font color="blue">process shipments</font> to customers</td>
    </tr>
    <tr>
      <td>If we     were  to  experience  a prolonged system <font color="blue">disruption</font> in the information     <font color="blue">technology</font>  systems  that  involve our <font color="blue">interactions with customers</font> and     suppliers, it could result in the loss of sales and customers, which could     <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>We are subject to economic, political and other <font color="blue">risks associated with</font> our     <font color="blue">significant</font> <font color="blue">international</font> sales and <font color="blue">operations</font>, which could <font color="blue"><font color="blue">adversely</font> affect</font>     our business</td>
    </tr>
    <tr>
      <td>We conduct <font color="blue">operations</font> <font color="blue">throughout</font> the <font color="blue">world through</font> a variety of <font color="blue">subsidiaries</font>     and <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>Sales outside the <font color="blue"><font color="blue">United States</font> </font>were <font color="blue">approximately</font> 65prca of     <font color="blue">total sales</font> in both 2005 and 2004</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our revenues,     <font color="blue">approximately</font>  40prca in 2005, is generated in Europe</td>
    </tr>
    <tr>
      <td>We anticipate that     revenue  from  <font color="blue">international</font>  <font color="blue">operations</font>  <font color="blue">will continue</font> to represent a     <font color="blue">significant</font>  portion  of our revenues</td>
    </tr>
    <tr>
      <td>In addition, two of our primary     <font color="blue">manufacturing</font> <font color="blue">facilities</font>, Molsheim, France and Cork, Ireland, and many of     our employees and suppliers, are located outside <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Our     sales and <font color="blue">earnings could</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by a variety of factors     resulting from our <font color="blue">international</font> <font color="blue">operations</font>, including:           •   changes in the political or <font color="blue">economic conditions</font> in a country or     region, particularly in developing or <font color="blue">emerging markets</font>;           •   <font color="blue">trade protection measures</font> and import or export licensing <font color="blue">requirements</font>;           •   <font color="blue">differing tax laws</font> and changes in those laws;           •   <font color="blue">difficult</font>y in staffing and managing widespread <font color="blue">operations</font>; and           •   differing <font color="blue">regulatory</font> <font color="blue">requirements</font> and changes in those <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Foreign exchange <font color="blue">fluctuations</font> may <font color="blue"><font color="blue">adversely</font> affect</font> our reported earnings,     the value of our assets and the costs of our <font color="blue">debt repayment</font></td>
    </tr>
    <tr>
      <td>We prepare our <font color="blue">consolidate</font>d financial statements in US dollars, but a     <font color="blue">significant</font>  portion  of  our  earnings  and <font color="blue">expenditures</font> are in other     currencies</td>
    </tr>
    <tr>
      <td>In 2005, we derived about 65prca of our <font color="blue">revenues from customers</font>     outside                                           19     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font><font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Our sales made in countries other than the <font color="blue"><font color="blue">United States</font> </font>    are typically made in the <font color="blue">local currencies</font> of those countries</td>
    </tr>
    <tr>
      <td>As a result,     <font color="blue">fluctuations</font>  in exchange rates have caused and <font color="blue">will continue</font> to cause     foreign currency <font color="blue">transaction</font> gains and losses</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in exchange     rates between the US dollar and other <font color="blue">currencies may also affect</font> the book     value of our <font color="blue">assets outside</font> <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>In addition, in 2005, we     borrowed €382 million under our <font color="blue">new revolving</font> credit <font color="blue">facility</font> denominated in     Euros</td>
    </tr>
    <tr>
      <td>We intend to repay in Euros from our European <font color="blue">profits denominated</font> in     Euros</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">such cash flow from</font> our <font color="blue">European     </font><font color="blue">operations</font> will be sufficient to <font color="blue">repay such debt</font>, in which case we may need     to repay from <font color="blue">profits denominated</font> in US dollars</td>
    </tr>
    <tr>
      <td>In such an event, a     <font color="blue">significant</font> appreciation of the Euro <font color="blue">with respect</font> to the US <font color="blue">dollar could</font>     expose us to <font color="blue">additional</font> foreign currency exposure</td>
    </tr>
    <tr>
      <td>Due to the number of     <font color="blue">currencies involved</font>, the <font color="blue">variability</font> of <font color="blue">currency exposures</font> and the potential     <font color="blue">volatility</font> of <font color="blue">currency exchange rates</font>, we <font color="blue">cannot predict</font> the effects of     exchange rate <font color="blue">fluctuations</font> on future operating results</td>
    </tr>
    <tr>
      <td>We seek to minimize     our  currency  <font color="blue">exposure by coordinating</font> our <font color="blue">worldwide supply sourcing</font>,     actively managing cross-border currency flows, and engaging in foreign     exchange  hedging  <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>Despite these steps, there can be no     assurance that our foreign currency management strategy will adequately     protect our operating results from the effects of <font color="blue">future exchange rate</font>     <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reduction </font>in our customers’ research and <font color="blue">development</font> budgets and <font color="blue">government</font>     funding may result in <font color="blue">reduced sales</font></td>
    </tr>
    <tr>
      <td>Our  customers include <font color="blue">researchers</font> at <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies, academic institutions and <font color="blue">government</font> and <font color="blue">private <font color="blue">laboratories</font></font>     <font color="blue">throughout</font> the world</td>
    </tr>
    <tr>
      <td>Their research and <font color="blue">development</font> budgets and <font color="blue">activities</font>     have  a  large  effect  on  the  demand for our products and services</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our customers’ research and <font color="blue">development</font> budgets occur due to     changes in available resources, mergers of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies, spending priorities and <font color="blue">institutional</font> <font color="blue">budgetary</font> policies</td>
    </tr>
    <tr>
      <td>Our     bioscience business could be <font color="blue"><font color="blue">adversely</font> impacted</font> by any <font color="blue">significant</font> decrease     in <font color="blue">life sciences research</font> and <font color="blue">development</font> <font color="blue">expenditures</font> by <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> companies, academic institutions or <font color="blue">government</font> and private     <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>In addition, short term changes in administrative, <font color="blue">regulatory</font>     or  purchasing-related  procedures  can  create <font color="blue">uncertainties</font> or other     <font color="blue">impediments which</font> can contribute to <font color="blue">lower sales</font></td>
    </tr>
    <tr>
      <td>A portion of our <font color="blue">bioscience sales</font> have been to <font color="blue">researchers</font>, universities,     <font color="blue">government</font>  <font color="blue">laboratories</font>  and <font color="blue">private foundations whose funding may</font> be     <font color="blue">dependent</font> in part upon grants from <font color="blue">government</font> agencies such as the US     National Institutes of Health (NIH) and similar domestic and <font color="blue">international</font>     agencies</td>
    </tr>
    <tr>
      <td>The annual NIH budget for 2006 was cut from its 2005 budget, the     <font color="blue">first such reduction</font> in 35 years</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that this trend will     change</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>funding of research and <font color="blue">development</font> is subject to the     political process, which is <font color="blue">inherently fluid</font> and unpredictable</td>
    </tr>
    <tr>
      <td>Our revenues     may be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if our <font color="blue">customers delay purchases as</font> a result of     <font color="blue">uncertainties</font> surrounding the approval of <font color="blue">government</font> or <font color="blue">industrial budget</font>     proposals</td>
    </tr>
    <tr>
      <td>If <font color="blue">researchers</font> were not able to obtain, for any <font color="blue">extended period</font>,     <font color="blue">government</font> funding <font color="blue">necessary</font> to purchase our products or if there is a     decrease in <font color="blue">overall research funding</font>, it <font color="blue">could reduce</font> our <font color="blue">bioscience sales</font>     and damage our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues may fluctuate</font>, and this <font color="blue">fluctuation could</font> cause financial     results to be below <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our operating results from period to period may occur for a     number of reasons</td>
    </tr>
    <tr>
      <td>In planning our operating expenses for the foreseeable     future, we assume that revenues <font color="blue">will continue</font> to grow</td>
    </tr>
    <tr>
      <td><font color="blue">Generally </font>operating     expenses  cannot be <font color="blue">adjusted quickly</font> in the short term because we have     <font color="blue">significant</font>  fixed  costs</td>
    </tr>
    <tr>
      <td>If  our <font color="blue">revenues decline</font> or do not grow as     anticipated,  we  may  not  be  able  to reduce our operating expenses     <font color="blue">accordingly</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  achieve anticipated levels of revenue could     therefore <font color="blue">significant</font>ly harm our operating results for a <font color="blue">particular period</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">revenue shortfall could</font> arise from any number of factors, some of which we     <font color="blue">cannot control</font></td>
    </tr>
    <tr>
      <td>For example, factors that may cause our results to vary by     period include:           •   the volume and timing of <font color="blue">orders from customers</font> for our products and     services;           •   the level and timing of our customers’ research and <font color="blue">commercialization</font>     efforts;           •   changes in the mix of our products and services;                                           20     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>  •   the number, timing and significance of <font color="blue">new products</font> and services     introduced by our customers;           •   our ability to develop, market and introduce new and enhanced products     and services on a <font color="blue">timely basis</font>;           •   changes in the cost, quality and <font color="blue">availability</font> of materials and     <font color="blue">components</font> required to <font color="blue">manufacture</font> or use our products;           •   the timing and costs of any <font color="blue">acquisition</font>s of <font color="blue">businesses</font> or     <font color="blue">technologies</font>;           •   the <font color="blue">introduction</font> of <font color="blue">new products</font> by us or our <font color="blue">competitors</font>,           •   exchange rate <font color="blue">fluctuations</font>; and           •   general <font color="blue">economic conditions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font>exposure to <font color="blue">product <font color="blue">liability</font></font> claims could <font color="blue"><font color="blue">adversely</font> affect</font> our     earnings</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> is a <font color="blue">major risk</font> in testing and marketing <font color="blue">bio<font color="blue">technology</font></font> and     <font color="blue">pharmaceutical</font> products offered by our customers</td>
    </tr>
    <tr>
      <td><font color="blue">Currently </font>these risks are     <font color="blue">primarily borne by</font> our customers</td>
    </tr>
    <tr>
      <td>As our products and services are further     integrated  into  our  customers’  <font color="blue">production processes</font>, we may become     <font color="blue">increasingly exposed</font> to <font color="blue">product <font color="blue">liability</font></font> and other claims in the event that     the use of our products or services is alleged to have resulted in adverse     effects</td>
    </tr>
    <tr>
      <td>There can be no assurance that a future <font color="blue">product <font color="blue">liability</font></font> claim or     series of claims <font color="blue">brought against us would</font> not have an adverse effect on our     business or the results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business may be <font color="blue">materially</font> and     <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by a successful <font color="blue">product <font color="blue">liability</font></font> claim or claims in     excess of any <font color="blue">insurance coverage</font> that we may have</td>
    </tr>
    <tr>
      <td>In addition, product     <font color="blue">liability</font> claims, <font color="blue">regardless</font> of their merits, could be costly and divert     management’s attention, and <font color="blue"><font color="blue">adversely</font> affect</font> our reputation and the demand     for our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">heavily rely on <font color="blue">air cargo carriers</font></font> and other <font color="blue">third party</font> package delivery     services, and a <font color="blue"><font color="blue">significant</font> <font color="blue">disruption</font></font> in these services or <font color="blue">significant</font>     increases in <font color="blue">prices may disrupt</font> our ability to <font color="blue">ship products</font> or import     materials, increase our costs and lower our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We ship a <font color="blue">significant</font> portion of our products to our <font color="blue">customers through</font>     in<font color="blue">dependent</font> package delivery companies</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">transport materials</font>     among  our  company <font color="blue">facilities</font>, including our <font color="blue">facilities</font> in France and     Ireland, and import <font color="blue"><font color="blue">raw materials</font> from</font> worldwide sources</td>
    </tr>
    <tr>
      <td>Consequently, we     heavily  rely  on  <font color="blue">air cargo carriers</font> and <font color="blue">third party</font> package delivery     providers</td>
    </tr>
    <tr>
      <td>If  any  of our key <font color="blue">third party</font> package delivery providers     experiences  a  <font color="blue">significant</font>  <font color="blue">disruption</font> such that any of our products,     <font color="blue">components</font> or <font color="blue">raw materials</font> would not be delivered in a <font color="blue">timely fashion</font> or we     would incur <font color="blue">additional</font> shipping costs that we could not pass on to our     customers, our <font color="blue">costs may increase</font> and our <font color="blue"><font color="blue">relationship</font>s</font> with certain of our     <font color="blue">customers may</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>In addition, if our <font color="blue">third party</font> package     <font color="blue">delivery providers increase prices</font>, and we are not able to <font color="blue">find comparable</font>     <font color="blue">alternatives</font> or make <font color="blue">adjustments</font> to our <font color="blue">delivery network</font>, our <font color="blue">profitability</font>     could be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>The stated value of long-lived and <font color="blue"><font color="blue">intangible asset</font>s</font> may become impaired and     result in an <font color="blue">impairment</font> charge</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we had <font color="blue">approximately</font> dlra380 million of long-lived     assets</td>
    </tr>
    <tr>
      <td>We continue to invest in the <font color="blue">construction</font> and upgrading of our     <font color="blue">manufacturing</font>  and  research  <font color="blue">facilities</font>  which may have the effect of     increasing the <font color="blue">recorded value</font> of our long-lived assets</td>
    </tr>
    <tr>
      <td>If we are successful     in  acquiring  <font color="blue">additional</font> complementary <font color="blue">businesses</font> and <font color="blue">technologies</font>, a     substantial portion of the value of these may be <font color="blue">recorded as goodwill</font>, an     <font color="blue">intangible asset</font></td>
    </tr>
    <tr>
      <td>The carrying amounts of long-lived and <font color="blue"><font color="blue">intangible asset</font>s</font>     are <font color="blue">affected whenever events</font> or changes in <font color="blue">circumstances indicate</font> that the     carrying amount of any asset may not be recoverable</td>
    </tr>
    <tr>
      <td>Such events or changes     might include a <font color="blue">significant</font> decline in market share, a <font color="blue">significant</font> decline     in profits, rapid changes in <font color="blue">technology</font>, failure to achieve the benefits of     <font color="blue">capacity</font> increases and utilization, <font color="blue">significant</font> litigation arising out of an     <font color="blue">acquisition</font> or other matters</td>
    </tr>
    <tr>
      <td>Adverse events or changes in <font color="blue">circumstances may</font>     affect the estimated <font color="blue">undiscounted future</font> operating <font color="blue">cash flows</font> expected to be     derived from long-lived and <font color="blue"><font color="blue">intangible asset</font>s</font></td>
    </tr>
    <tr>
      <td>If at any time we determine     that an <font color="blue">impairment</font> has occurred, we will be required to reflect the impaired     value as a charge, resulting in a reduction in earnings in the <font color="blue">quarter such</font>     <font color="blue">impairment</font> is identified and a <font color="blue">corresponding reduction</font> in our net asset     value</td>
    </tr>
    <tr>
      <td>The <font color="blue">potential recognition</font> of <font color="blue">impairment</font> in the carrying value, if     any, could have a material and <font color="blue">adverse affect on</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>Our level of debt could limit cash flow available for our <font color="blue">operations</font> and     could <font color="blue"><font color="blue">adversely</font> affect</font> our ability to service our debt or obtain <font color="blue">additional</font>     financing, if <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, our total debt was dlra552 million</td>
    </tr>
    <tr>
      <td>We     <font color="blue">recently established</font> a revolving credit <font color="blue">facility</font> against which we can borrow     in  either  the  United  States  or  Europe, up to a <font color="blue">maximum corporate</font>     <font color="blue">availability</font> of €430 million</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we had drawn dlra452     million (€382 million) on this credit <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>At such time as all or a     substantial portion of the <font color="blue">proceeds from</font> this credit <font color="blue">facility</font> were to be     expended and our <font color="blue">cash position reduced commensurately</font>, our level of debt     <font color="blue">could restrict</font> our <font color="blue">operations</font> and make it more <font color="blue">difficult</font> for us to satisfy     our <font color="blue">obligations</font>, including under the notes</td>
    </tr>
    <tr>
      <td>Among other things, our level of     debt  may  expose us to the risk of <font color="blue">increased interest rates</font> because a     substantial portion of our debt has <font color="blue">variable interest rates</font></td>
    </tr>
    <tr>
      <td>We  may  require  substantial  <font color="blue">additional</font>  capital to <font color="blue">pursue strategic</font>     <font color="blue">acquisition</font>s or alliances, which capital we may not be able to obtain on     <font color="blue">commercially</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>We  anticipate that our currently planned capital <font color="blue">requirements</font> will be     <font color="blue">satisfied by</font> the future operating cash flow, current cash balances or other     existing  financing  sources</td>
    </tr>
    <tr>
      <td>To the extent that we desire to pursue a     strategic <font color="blue">acquisition</font> or alliance requiring substantial cash <font color="blue">expenditures</font>     for which our existing resources and credit <font color="blue">facilities</font> are insufficient, we     may need to raise funds through public or private debt or equity <font color="blue">financings</font></td>
    </tr>
    <tr>
      <td>There is no assurance that such <font color="blue">additional</font> funds will be available or, if     available, that we can obtain <font color="blue">such funds on terms</font> acceptable to us</td>
    </tr>
    <tr>
      <td>If  adequate  funds  are  not  available, we may have to forgo desired     <font color="blue">acquisition</font>s  or  alliances,  or  reduce <font color="blue">expenditures</font> for research and     <font color="blue">development</font>, production or marketing, which could have an adverse effect on     our business</td>
    </tr>
    <tr>
      <td>To the extent that <font color="blue">additional</font> capital is raised through the     sale of equity or convertible securities, the issuance of such securities     could result in dilution to our <font color="blue">shareholders</font></td>
    </tr>
  </tbody>
</table>